Trial Profile
A Phase I, First-in-Human Clinical Trial of AB 101 (Insulin) in Subjects with Type 1 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Rezolute
- 18 Dec 2019 Status changed to completed, according to a Rezolute media release.
- 18 Dec 2019 Topline results presented in a Rezolute media release.
- 07 Jan 2019 According to a Rezolute media release, the company entered $25 million preferred stock purchase agreement with Handok, Inc., and Genexine, Inc. These proceeds will be utilized to complete this study.